Posted by Michael Wonder on 15 Feb 2022
ICER publishes final evidence report and policy recommendations on tirzepatide for type 2 diabetes
15 February 2022 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added to background therapy in individuals with type 2 diabetes.
The Institute for Clinical and Economic Review today released a final evidence report assessing the comparative clinical effectiveness and value of tirzepatide (Eli Lilly) for the treatment of type 2 diabetes.
